Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination

Br J Dermatol. 2022 Aug;187(2):271-273. doi: 10.1111/bjd.21240. Epub 2022 May 24.

Authors

Morgan Birabaharan¹, David C Kaelber², Charisse M Orme³, Taraneh Paravar³, Maile Y Karris¹

Affiliations

¹ Division of Infectious Diseases and Global Public Health, Department of Medicine.
² Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
³ Department of Dermatology, University of California, San Diego, La Jolla, CA, USA.

No abstract available

Publication types

Letter

MeSH terms

COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Humans
Pemphigoid, Bullous* / etiology
RNA, Messenger

Substances

COVID-19 Vaccines
RNA, Messenger

Grants and funding